From the editor


Greener pharma T


On the web...


Keep up with the latest developments across the industry by visiting www.worldpharmaceuticals.net


World Pharmaceutical Frontiers 2025 Vol. 2


Editorial


Editor-in-chief Thom Atkinson thom.atkinson@btmi.com


Contributors Jim Banks, Liam Critchley, Sarah Harris, Natalie Healey, Monica Karpinski, Ellie Philpotts, Sachin Rawat, Claire Read, Kim Thomas


Designer Martin Faulkner Art director Henrik Williams Production manager Dave Stanford


Commercial


Publication manager Nathan Park nathan.park@btmi.com


Division sales manager Martin John martin.john@btmi.com


World Pharmaceutical Frontiers is published by Business Trade Media International, a division of GlobalData Media. Registered in England No. 06212740. ISSN 1742-3791 © 2025


All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, photocopying or otherwise, without prior permission of the publisher and copyright owner. While every effort has been made to ensure the accuracy of the information in this publication, the publisher accepts no responsibility for errors/omissions.


The products and services advertised are those of individual authors and are not necessarily endorsed by or connected with the publisher. The opinions expressed in the articles within this publication are those of individual authors and not necessarily those of the publisher.


Subscription records are maintained at Business Trade Media International.


SUBSCRIPTIONS


Single issue price: UK £44 EU €68 US $89 RoW $89 One year: Two year:


Email: cs@btmi.com


John Carpenter House, John Carpenter St, Temple, London EC4Y 0AN Tel: +44 207 936 6400


Printed by Stephens & George Print Group


UK £67 EU €104 US $135 RoW $136 UK £105 EU €163 US $215 RoW $216


Thom Atkinson, editor-in-chief


he pharmaceutical industry has always been defined by its pursuit of precision, safety and innovation. Yet today, a new pillar is reshaping that structure: sustainability. From the lab bench to the supply chain, the sector is being challenged to deliver life-saving therapies without compromising the health of the planet.


In peptide manufacturing, this shift is already under way (see page 67). As the global peptide therapeutics market accelerates – driven by the success of drugs like semaglutide and tirzepatide – scientists are rethinking the chemistry behind the process itself. Traditional synthesis methods rely heavily on hazardous solvents and generate substantial waste. Researchers are now advancing greener approaches that improve coupling efficiencies, reduce solvent use and view manufacturing through a holistic sustainability lens. The goal is clear: to make the next generation of peptide medicines not just powerful, but planet-friendly. But greener chemistry is only one piece of the puzzle. Across the industry, companies are navigating the complex intersection of sustainability and compliance. Regulatory frameworks, built primarily to safeguard patients, are now being reinterpreted to include environmental stewardship. As Roche’s Michaela Fuetsch notes on page 10, aligning drug development and delivery systems with evolving sustainability legislation – such as the EU’s Green Deal – requires collaboration between regulators, manufacturers and policymakers alike. The industry’s ability to innovate sustainably will depend on how effectively these relationships evolve.


Even the cold chain, long regarded as a symbol of pharmaceutical precision, is under scrutiny. As Sarah Harris reports on page 23, temperature-controlled packaging now sits at the crossroads of two imperatives: suitability and sustainability. New materials, circular systems and smarter logistics are being explored to reduce waste while maintaining product integrity – a balancing act that may define the future of pharmaceutical distribution. From greener synthesis to regulatory evolution and sustainable packaging, one message is emerging: the journey to a low-impact, high-integrity pharmaceutical industry is well under way. What’s changing is not the commitment to science and safety – but how those principles are applied in a world that can no longer afford to see health and environmental responsibility as separate goals. So, I invite our readers to explore how innovation, regulation and collaboration are converging to make pharma truly green.


www.worldpharmaceuticals.net


3


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85